The HemOnc Pulse Live at ASH: Thomas Martin, MD, on Frontline Treatment Advances, Novel Agents in Myeloma
By Chadi Nabhan, MD, MBA, FACP, Thomas Martin, MD - Last Updated: January 10, 2023The HemOnc Pulse, brought to you by Blood Cancers Today and the Society of Hematologic Oncology, checks in with Blood Cancers Today Editorial Board Member Thomas Martin, MD, during the 64th Annual American Society of Hematology Meeting and Exhibition. Dr. Martin discussed topics including advances in frontline treatments for multiple myeloma, the use of CD38-directed antibodies in patients with relapsed disease, combination therapies with bispecific T-cell engagers, the need for novel agents, and more, with host Chadi Nabhan, MD, MBA, FACP.
Advertisement
Post Tags:Myeloma ASH 22
Advertisement
Related Posts
Kelly Chien, MD, discusses how disparities in access to care, resources, and molecular testing impact outcomes in AML.
Anderw Brunner, MD addresses current gaps in MDS research and clinical practice and more.
Nirav Shah, MD, MSHP, tells BCT about his team's phase I/II clinical trial findings.
Sairah Ahmed, MD, tells about current management challenges and promising developments in treatment options.
Seta Degann, MD, resident physician at George Washington University, described the challenges of diagnosing younger patients.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.